News

    • BioGenCell receives grant from Pace University Lubin School of Business/ MIT Enterprise Forum for Israel.
      A $250,000 grant from Philanthropist Michael Dezer will provide Pace students from a variety of disciplines the opportunity to work closely with entrepreneurs from Israel while assisting their companies business development.  Six student fellows will be chosen to provide research, analysis, product testing, and additional support to two Israel-based companies that have been selected to participate in the program.  Through working with the partner companies, BioGenCell Ltd. and FreshBiz, not only will the students earn a stipend, but they will have the unique opportunity to closely interact with the business leadership teams, thus gaining valuable insights and real-world experience. The Pace entrepreneurship Lab implemented this initiative in association with the MIT Enterprise forum of Israel The Forum and its associated chapters in 28 countries comprise a global non-profit organization dedicated to promoting the growth and success of high-tech entrepreneurial ventures by connecting ideas, technology and people.

      Development of a Stem Cell Therapy Product – Dr. Yael Porat Speaking at Pace University, NY

    • BioGenCell Raises $1mThe company was founded a year ago on the basis of research by CEO Dr. Yael Porat, formerly CTO of stem cell firm TheraVitae Company Ltd.  BioGenCell’s product aims to treat blood flow problems in the limbs, a side effect of diabetes and heart disease. The product’s uniqueness is the use of autologous cells (cells derived from the patients themselves) to repair themselves. The company’s technology separates cells that have not yet undergone full cell speciation using special receptors found only in these cells. Porat said, “Cells from an adult include stem and early-stage cells. The company’s product is a mid-stage cell, which has already partly speciated, but still has some degree of flexibility.”
    • The US Presidential Commission for the Study of Bioethical Issues’ web site cites Dr. Porat’s article in the British Journal of Haematology in its list of “New Advances in Non-Embryonic Stem Cell Research”.